APA (7th ed.) Citation

Müller-Tidow, C., Bug, G., Lübbert, M., Krämer, A., Krauter, J., Valent, P., . . . Döhner, H. (2013). A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. British journal of haematology, 163(2), . https://doi.org/10.1111/bjh.12518

Chicago Style (17th ed.) Citation

Müller-Tidow, Carsten, et al. "A Randomized, Open-label, Phase I/II Trial to Investigate the Maximum Tolerated Dose of the Polo-like Kinase Inhibitor BI 2536 in Elderly Patients with Refractory/relapsed Acute Myeloid Leukaemia." British Journal of Haematology 163, no. 2 (2013). https://doi.org/10.1111/bjh.12518.

MLA (9th ed.) Citation

Müller-Tidow, Carsten, et al. "A Randomized, Open-label, Phase I/II Trial to Investigate the Maximum Tolerated Dose of the Polo-like Kinase Inhibitor BI 2536 in Elderly Patients with Refractory/relapsed Acute Myeloid Leukaemia." British Journal of Haematology, vol. 163, no. 2, 2013, https://doi.org/10.1111/bjh.12518.